Earnings
Several biopharma companies announced Series B financing rounds or additional investment raises. Here’s a look.
Mammoth will use the funds to build and broaden its stable of next-generation CRISPR products to detect and cure various diseases.
Acorda Therapeutics is reducing its staff count by 15% effective immediately as it struggles to bring operating costs down and hit expected revenue.
Laronde has managed to secure as much as $440 million from a Series B financing round to support as many as 100 Endless RNA (eRNA) products and drug programs over the next decade.
The combined company out of the Humacyte SPAC will be called Humacyte and is expected to trade shares of common stock and warrants on the Nasdaq Global Select Market.
Funds will be used to advance the clinical development of Cardior’s lead program, CDR132L, an oligonucleotide-based ncRNA inhibitor targeting micro-RNA-132.
Under the terms of the deal, Pfizer is picking up all outstanding shares of Trillium that it doesn’t already own for $18.50 per share in cash.
Ginkgo has signed multiple collaborations, announced a breakthrough in manufacturing mRNA vaccine components, and landed an SPAC deal.
The companies will use their funds to support the development of their lead assets and advance their pipelines.
The latest biopharma insider trading scandal stems from Pfizer’s acquisition of Medivation in 2016.
PRESS RELEASES